Rezera Inc.
Rezera Inc., formerly NodThera Inc., filed an S-1 registration for an initial public offering on Nasdaq under the symbol "RZRA." The clinical-stage biotech is developing wholly-owned oral NLRP3 inhibitors, with lead candidate ruvonoflast targeting peripheral artery disease (PAD) and a Phase 3 trial planned for H1 2027. The offering is underwritten by Jefferies, TD Cowen, and Cantor, with Wedbush and PacGrow as co-managers; pricing terms and share count remain blank.
- Rezera is a clinical-stage biotech developing oral NLRP3 inhibitors for cardiovascular and neuroinflammatory diseases.
- Lead candidate ruvonoflast targets peripheral artery disease (PAD), a ~$5B market opportunity affecting ~20M U.S. adults.
- Ruvonoflast reduced hsCRP by 82% vs. 37% placebo in a calorie-restricted high-CV-risk trial; Phase 3 PAD trial planned for H1 2027.
- Second candidate trabzanoflast (NT-0150) is a brain-penetrant NLRP3 inhibitor that completed Phase 1 for neuroinflammatory indications.
- The company changed its name from NodThera Inc. to Rezera Inc. effective September 9, 2026.
Price data unavailable.
A decade-old NLRP3 pure-play with wholly-owned oral candidates enters public markets, targeting a $5B PAD opportunity with no approved anti-inflammatory therapies.
The NLRP3 inflammasome space has attracted significant biotech investment, with competitors pursuing both oral small molecules and injectable biologics. Rezera's wholly-owned, internally-invented portfolio and decade-plus head start in NLRP3 research position it as a pure-play entrant in the anti-IL
No clinical trials have been conducted in PAD patients; all biomarker data comes from non-PAD populations. The company has no approved products, no revenue, and is entirely dependent on IPO proceeds to fund operations and the planned Phase 3 trial.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.